Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.
22 November 2023 in I.P. Pavlov Russian Medical Biological Herald
Introduction: Vertebrogenic pain syndromes (PSs) in the lower back (LB) are among the most common neurological disorders in the population. Currently, clinical, neurophysiological and neuroimaging characteristics are used as predictors of the course and effectiveness of the treatment for vertebrogenic PSs in the LB. Aim: To identify the neurophysiological factors associated with compression and reflex mechanisms of PSs in the LB for their differentiation in complicated diagnostic cases. Materials and methods: The study included 73 patients, 43 of them men and 30 women of the mean age 46.5 years. Based on the results of clinical neurological examination and the magnetic resonance imaging data, reflex vertebrogenic PSs (lumboischialgia) were verified in 40 cases, and radiculopathy of L5 and/or S1 (compression vertebrogenic PSs) in 33 cases. The patients underwent stimulation electroneuromyography with record of motor and sensory responses from the lower limbs, of F- and H-response, and examination of heart rate variability. Results: Logit regression analysis was used to create models permitting to divide patients into groups with different mechanisms of PSs based on the neurophysiological parameters. The first model demonstrated high sensitivity in the identification of predominantly compression vertebrogenic disorders with the independent factors being the mean F-wave latency and the sensory response amplitude. The second model was more sensitive in identification of reflex PSs with the main predictors being the F-response amplitude and heart rate variability parameters. Conclusion: The identified factors reflect the role of conduction disorders in compression PSs, as well as the involvement of segmental motor neuronal apparatus and autonomic regulatory mechanisms in the reaction in reflex PSs, which are additional sources of information in taking medical decisions in complicated diagnostic cases.
30 September 2025 in Nauka Molodykh (Eruditio Juvenium)
INTRODUCTION: Systemic thrombolysis is an effective and safe method of reperfusion therapy in ischemic stroke. However, the effectiveness and safety of different thrombolytic drugs are not the same. It is relevant to analyze the use of systemic thrombolytics in real clinical practice of the Regional Vascular Center. AIM: To compare the effectiveness and safety of thrombolytic therapy (TLT) with non-immunogenic staphylokinase (forteplase) and tissue plasminogen activator (alteplase) in patients with acute ischemic stroke hospitalized in the Regional Vascular Center. MATERIALS AND METHODS: A retrospective analysis of medical histories of 60 patients of the Regional Vascular Center was conducted. Group 1 (33 patients) received non-immunogenic staphylokinase, group 2 (27 patients) — alteplase. The groups had no statistically significant differences except for a higher incidence of diabetes in group 1. Before TLT and on day 1 after, neurologic deficit was evaluated on NIHSS scale, and clinical outcomes on the modified Rankin scale; evaluation on rehabilitation routing scale (RRS) was conducted on day 10. Safety of systemic thrombolysis was assessed by the existence of hemorrhagic complications, the development of a fatal outcome. RESULTS: In group 1 a statistically significant positive dynamics was obtained on day 1 on NIHSS, Rankin scale and on day 10 on RRS. One case of hemorrhagic transformation with a fatal outcome was recorded. In group 2 no statistically significant dynamics in the above parameters was recorded. Intracerebral hematoma and hemorrhagic transformation in 2 patients (7.4%). Fatal outcome at the hospital stage was statistically significantly more frequent in group 2 — 11 patients (40.7%) versus 6 patients (18.1%). CONCLUSION: The conducted retrospective comparative analysis of TLT in the acute period of ischemic stroke showed a higher effectiveness compared to alteplase, no less safety of non-immunogenic staphylokinase in terms of hemorrhagic complications, and lower mortality in the staphylokinase group in the hospital observation period.
24 May 2025 in Meditsinskiy sovet = Medical Council
Recently, the number of myocardial infarctions and strokes in young patients has been increasing. Most often these are non-atherogenic causes: congenital heart defects, coagulopathies, arteritis, etc. To discuss the difficulties of diagnosing the causes of strokes and myocardial infarctions in young patients, we present a clinical case of a 39-year-old patient with atrial septal defect and genetic thrombophilia, which resulted in myocardial infarction and embolic stroke. A special feature of this clinical case can be considered the fact of the development of embolic myocardial infarction during pregnancy in a patient with atrial septal defect surgery in childhood. However, the study on thrombophilia was not complete after a miscarriage during the first pregnancy. Suspicions of the formation of a right-left shunt were confirmed upon hospitalization due to embolic myocardial infarction. After cesarean delivery, endovascular occlusion of the atrial septal defect with an occluder was performed, and 4 years after the installation of the occluder, the patient developed an embolic stroke, as evidenced by the multiplicity of ischemic foci of the brain during imaging studies. Examination for thrombophilia after a repeated ischemic event revealed homozygous mutations in factor VII (A/A), FGB (A/A), heterozygous mutations in folate cycle genes (C/T polymorphism in the MTHFR gene, A/G polymorphism in the MTR gene), heterozygous polymorphism in the PAI-1 gene (4G/5G). The hematologist recommended constant anticoagulant therapy rivaroxaban at a dose of 2.5 mg 2 times a day. The described clinical case demonstrates the polyethology and complexity of the pathogenetic mechanisms of myocardial infarction and stroke in a young patient. If these events occur in young people, it is important to perform echocardiography (with a bubble test, if necessary), daily monitoring of electrocardiography, and laboratory examination for thrombophilia.
30 August 2026 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
The development of reperfusion methods for the treatment of cerebral infarction, the emergence of new drugs for thrombolytic therapy, and the expansion of indications for reperfusion require a comparative analysis of the effectiveness and safety of various therapeutic methods to achieve optimal treatment tactics and improve the prognosis. The purpose of this study was to evaluate the efficacy and safety of various reperfusion therapy methods in patients with ischemic stroke. The clinical records of 98 patients with ischemic stroke in the middle cerebral artery system were analyzed for clinical and neuroimaging parameters. Patients were divided into groups based on the type of reperfusion therapy and short-term outcome. The nonparametric Mann-Whitney U test was used to assess statistical differences between parameters in the different groups; differences were considered significant at p < 0.05. Different methods of reperfusion therapy showed no significant differences in clinical criteria, with the exception of the volume of ischemic damage. Patients who received thrombolytic therapy with non-immunogenic staphylokinase (Fortelyzin) demonstrated high efficacy rates with a low incidence of hemorrhagic transformation. Prognostically significant factors included the severity and degree of regression of neurological deficit, level of consciousness, and the extent of ischemic brain damage. Hemorrhagic transformation of the ischemic focus is associated with higher mortality but the type of the hemorrhagic transformation influences the prognoses of the survivors.